Business
Currency:USD
2024/Q2
Stock NameRevenueRatio
Xywav368.47M35.99%
Epidiolex/Epidyolex247.1M24.14%
Rylaze/Enrylaze107.83M10.53%
Zepzelca81.05M7.92%
Xyrem62.18M6.07%
High-sodium oxybate AG royalty revenue54.16M5.29%
Defitelio/defibrotide45.42M4.44%
Vyxeos43.01M4.20%
Other8.22M0.80%
Sativex6.38M0.62%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States3.49B91.02%
Europe269.24M7.02%
All other74.98M1.96%
